文章：

FGFR3在膀胱癌进展中的作用

The Role of FGFR3 in the Progression of Bladder Cancer

原文发布日期：6 November 2025

DOI: 10.3390/cancers17213588

类型: Article

开放获取: 是

英文摘要：

Introduction:Bladder cancer is associated with a high recurrence rate, and outcomes for muscle-invasive and metastatic disease remain poor. New targeted therapies, such as the FGFR inhibitor erdafitinib, have been introduced, but the progression from non-muscle-invasive to muscle-invasive disease remains a major clinical challenge.Methods:In this study, we performed immunohistochemical staining for FGFR1-FGFR4 on surgical specimens from 192 cases of urothelial carcinoma. We also conducted various functional assays on human bladder cancer cell lines to assess protein/gene expression, cell proliferation, migration, invasion, and colony formation.Results:FGFR2 and FGFR3 expressions were found to be significantly down-regulated in high-grade (0.014) and muscle-invasive (0.002) tumors, respectively. Functionally, the FGFR inhibitor erdafitinib suppressed cell proliferation and migration, and FGFR3 silencing also markedly reduced proliferation, migration, invasion, and colony formation in cancer cell lines.Conclusions:The down-regulation of FGFR3 in muscle-invasive bladder cancer, coupled with the inhibitory effect of its inactivation on cell growth, suggests a significant role for FGFR3 in bladder cancer progression.

摘要翻译： 

引言：膀胱癌具有高复发率，肌层浸润性和转移性疾病的预后仍然较差。尽管已引入如FGFR抑制剂厄达替尼等新型靶向疗法，但非肌层浸润性疾病向肌层浸润性疾病的进展仍是临床面临的主要挑战。 方法：本研究对192例尿路上皮癌手术标本进行了FGFR1-FGFR4的免疫组化染色，并在人膀胱癌细胞系中进行了多种功能实验，以评估蛋白/基因表达、细胞增殖、迁移、侵袭及克隆形成能力。 结果：研究发现，高级别肿瘤中FGFR2表达显著下调（P=0.014），肌层浸润性肿瘤中FGFR3表达显著下调（P=0.002）。功能实验表明，FGFR抑制剂厄达替尼可抑制细胞增殖和迁移，而沉默FGFR3同样显著降低了癌细胞系的增殖、迁移、侵袭及克隆形成能力。 结论：FGFR3在肌层浸润性膀胱癌中的下调表达，及其失活对细胞生长的抑制作用，提示FGFR3在膀胱癌进展中具有重要作用。

原文链接：

The Role of FGFR3 in the Progression of Bladder Cancer